论文部分内容阅读
目的探讨长春瑞滨联合奈达铂治疗晚期鼻咽癌的临床效果及安全性。方法选取晚期鼻咽癌患者44例,随机分为治疗组和对照组,各22例。对照组于入院1~5 d给予静脉滴注5-氟尿嘧啶500 mg/m~2+0.9%氯化钠注射液500 ml联合顺铂20 mg/m~2+0.9%氯化钠溶液500 ml。治疗组于入院第1天和第8天给予静脉滴注长春瑞滨(25~30 mg/m~2,30 min内完成)联合奈达铂100 mg/m~2,第1天长春瑞滨滴注前后,将硫酸镁(25%,4 ml)、利多卡因(2%,4 ml)溶于0.9%氯化钠溶液250 ml静脉滴注。两组均化疗3个周期(21 d为1个周期),疗程结束后评价两组疗效及不良反应发生率。结果两组化疗3个周期后,对照组客观有效率为36.35%,治疗组为72.72%,两组比较,P<0.05。两组主要不良作用为血液学毒性和口腔黏膜溃疡,但两组Ⅲ、Ⅳ级不良作用发生率差异无统计学意义(P均>0.05)。结论长春瑞滨联合奈达铂治疗晚期鼻咽癌客观有效率高,不良作用少。
Objective To investigate the clinical efficacy and safety of vinorelbine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma. Methods Forty-four patients with advanced nasopharyngeal carcinoma were randomly divided into treatment group and control group, with 22 cases in each group. In the control group, 500 ml of 5-Fluorouracil 500 mg / m ~ 2 + 0.9% Sodium Chloride Injection and 500 ml of cisplatin 20 mg / m ~ 2 + 0.9% Sodium Chloride solution were given intravenously 1 to 5 days after admission. The patients in the treatment group were given intravenous infusion of vinorelbine (25-30 mg / m 2, within 30 min) and 100 mg / m 2 of nedaplatin on day 1 and 8 of admission. On the first day, vinorelbine Before and after instillation, magnesium sulfate (25%, 4 ml), lidocaine (2%, 4 ml) dissolved in 0.9% sodium chloride solution 250 ml intravenously. The two groups were 3 cycles of chemotherapy (21 d for a cycle), after the end of the course of treatment efficacy and adverse reactions were evaluated. Results After three cycles of chemotherapy, the objective effective rate was 36.35% in the control group and 72.72% in the treatment group, P <0.05. The main adverse effects of both groups were hematological toxicity and oral mucosal ulcer, but there was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion Vinorelbine combined with nedaplatin in the treatment of advanced nasopharyngeal carcinoma objective and efficient, less adverse effects.